Showing results (441-450 of 734) with videos related to

Sort By:
Pageof 74
Cancer Medicine|February 8, 2023
Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T-cell therapy recipientsMarissa Z Powell, Kristin C Mara, Radhika Bansal, et al.
Blood|July 27, 2001
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphomaL F Porrata, M A Gertz, D J Inwards, et al.
British Journal of Haematology|April 7, 2009
Risk of non-Hodgkin lymphoma in association with germline variation in complement genesJames R Cerhan, Anne J Novak, Zachary S Fredericksen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2005
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphomaThomas E Witzig, Susan M Geyer, Irene Ghobrial, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2009
Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphomaStephen M Ansell, Sara A Hurvitz, Patricia A Koenig, et al.
Blood|July 28, 2019
Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphomaYucai Wang, Brian K Link, Thomas E Witzig, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 27, 2012
Effects of block copolymer properties on nanocarrier protection from in vivo clearanceSuzanne M D'Addio, Walid Saad, Steven M Ansell, et al.
Blood|July 15, 2009
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disordersRyan A Wilcox, Andrew L Feldman, David A Wada, et al.
American Journal of Hematology|March 16, 2010
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphomaPatrick B Johnston, David J Inwards, Joseph P Colgan, et al.
Leukemia|April 28, 2023
Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphomaTheodora Anagnostou, Zhi-Zhang Yang, Shahrzad Jalali, et al.
Pageof 74